Skip to main content

New test to diagnose early stage Alzheimer's disease

A new test has been developed that measures amyloid-beta oligomers in the cerebrospinal fluid, promising a reliable means of early diagnosis.

A new test has been developed that measures amyloid-beta oligomers in the cerebrospinal fluid, promising a reliable means of early diagnosis. In a comparison of patients with Alzheimer’s, patients with MCI that later developed into Alzheimer’s, and controls, levels of these protein fragments directly correlated with Alzheimer’s, and was more accurate than levels of the more usual amyloid plaques.

http://www.eurekalert.org/pub_releases/2010-03/foas-ntt032510.php

Reference

Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., … Nakagawa, M. (2010). High-molecular-weight {beta}-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J., fj.09-150359 . Retrieved from http://www.fasebj.org/cgi/content/abstract/fj.09-150359v1

seniors
alzheimers-diagnosis
Alzheimers

Related News

Late-life depression increases dementia risk

Submitted by Fiona McPherson on

Late-life depression is associated with an increased risk for all-cause dementia, Alzheimer’s disease, and, most predominantly, vascular dementia, a new study shows.

A new meta-analysis extends previous research showing a link between depression and Alzheimer’s disease to late-life depression and dementia. The analysis of 23 studies concluded that those with late-life depression were significantly more likely to develop dementia (1.85 times more likely), and that the risk of developing vascular dementia was significantly greater than that of developing Alzheimer’s (2.52 vs 1.65).

Alzheimer's diagnostic guidelines updated

For the first time in 27 years, clinical diagnostic criteria for Alzheimer's disease dementia have been revised, and research guidelines updated. They mark a major change in how experts think about and study Alzheimer's disease.

The updated guidelines now cover three distinct stages of Alzheimer's disease:

Review confirms early diagnosis tool

A survey of more than 100 studies involving PIB-PET, a diagnostic tool that involves injecting a radiotracer called Pittsburgh compound B into the brain via the bloodstream, and imaging the brain with positron emission tomography (PET), has confirmed its sensitivity in detecting amyloid-beta protein plaques. The tool is not yet commercially available. The study also provides strong evidence supporting the theory that accumulation of amyloid-beta protein plaques in the brain is central to the development of Alzheimer’s.

Predicting if MCI will progress to Alzheimer's

Submitted by Fiona McPherson on

A French study has predicted with 90% accuracy which patients with mild cognitive impairment would receive a clinical diagnosis of Alzheimer's disease within the following two years. The best neurological predictors were cortical thickness in two brain regions (the right anterior cingulate and middle frontal gyri), and the best cognitive predictors were deficits in both free recall and recognition episodic memory. Combining these measures achieved the highest accuracy.

Default mode network changes predict Alzheimer’s

Submitted by Fiona McPherson on

Data from 848 adults of all ages has found that brain volume in the default mode network declined in both healthy and pathological aging, but the greatest decline occurred in Alzheimer’s patients and in those who progressed from mild cognitive impairment to Alzheimer’s disease. Reduced brain volumes in these regions were associated with declines in cognitive ability, the presence of Alzheimer’s biomarkers in the cerebrospinal fluid, and with carrying the “Alzheimer’s gene”, the APOE4 allele.

Memory complaints linked to higher risk of MCI & dementia

Submitted by Fiona McPherson on

Data from 6257 older adults (aged 55-90) evaluated from 2005-2012 has revealed that concerns about memory should be taken seriously, with subjective complaints associated with a doubled risk of developing mild cognitive impairment or dementia, and subjective complaints supported by a loved one being associated with a fourfold risk. Complaints by a loved one alone were also associated with a doubled risk. Among those with MCI, subjective complaints supported by a loved one were associated with a threefold risk of converting to dementia.

Smell tests provide early evidence of dementia

In the past few months, several studies have come out showing the value of three different tests of people's sense of smell for improving the accuracy of MCI and Alzheimer's diagnosis, or pointing to increased risk. The studies also add to growing evidence that a decline in sense of smell is an early marker for mild cognitive impairment and Alzheimer’s. Indeed, it appears that this sensory loss is a very early symptom, preceding even the shrinking of the entorhinal cortex (the first brain region to show signs of atrophy).

Down Syndrome risk of Alzheimer’s connected to white matter integrity

Submitted by Fiona McPherson on

Brain scans of 10 persons with Down syndrome but no dementia, 10 persons with Down syndrome and dementia, and 10 healthy controls, have revealed a linear correlation between cognitive ability and compromised white matter connections in the frontal lobes among those with Down syndrome. Those with higher cognitive ability and motor skill coordination had healthier white matter integrity, and those with additional dementia showed the most deterioration.

Adults with Down Syndrome are known to be at high risk of developing Alzheimer’s after age 40.